About Inhibikase Therapeutics, Inc.
https://www.inhibikase.comInhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.
CEO
Mark T. Iwicki
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-30 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
SANDS CAPITAL VENTURES, LLC
Shares:10.95M
Value:$18.61M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:6.33M
Value:$10.75M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:6.13M
Value:$10.41M
Summary
Showing Top 3 of 57
About Inhibikase Therapeutics, Inc.
https://www.inhibikase.comInhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.24M ▲ | $-11.93M ▼ | 0% | $-0.13 ▼ | $-11.91M ▼ |
| Q2-2025 | $0 | $10.83M ▼ | $-9.92M ▲ | 0% | $-0.11 ▲ | $-11.17M ▲ |
| Q1-2025 | $0 | $14.6M ▲ | $-13.68M ▼ | 0% | $-0.15 ▲ | $-15.75M ▼ |
| Q4-2024 | $0 | $12.92M ▲ | $-12.13M ▼ | 0% | $-0.17 ▲ | $-12.13M ▼ |
| Q3-2024 | $0 | $5.83M | $-5.78M | 0% | $-0.65 | $-5.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $77.32M ▼ | $79.59M ▼ | $6.7M ▼ | $72.9M ▼ |
| Q2-2025 | $87.67M ▼ | $88.85M ▼ | $8.8M ▲ | $80.05M ▼ |
| Q1-2025 | $93.18M ▼ | $94.28M ▼ | $8.55M ▲ | $85.73M ▼ |
| Q4-2024 | $97.54M ▲ | $98.6M ▲ | $3.73M ▼ | $94.87M ▲ |
| Q3-2024 | $3.24M | $4.38M | $4.91M | $-530.59K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.93M ▼ | $-10.59M ▼ | $-28.75M ▼ | $-134.13K ▼ | $-39.47M ▼ | $-10.59M ▼ |
| Q2-2025 | $-9.92M ▲ | $-5.57M ▼ | $9.84M ▼ | $31.77K ▲ | $4.3M ▼ | $-5.57M ▼ |
| Q1-2025 | $-13.68M ▼ | $-4.1M ▲ | $21.05M ▲ | $0 ▼ | $16.95M ▼ | $-4.1M ▲ |
| Q4-2024 | $-12.13M ▼ | $-5.35M ▼ | $-38.76M ▼ | $99.68M ▲ | $55.58M ▲ | $-5.35M ▼ |
| Q3-2024 | $-5.78M | $-4.88M | $2.53M | $181.95K | $-2.17M | $-4.88M |
CEO
Mark T. Iwicki
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-06-30 | Reverse | 1:6 |
ETFs Holding This Stock
Summary
Showing Top 3 of 40
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
SANDS CAPITAL VENTURES, LLC
Shares:10.95M
Value:$18.61M
SOLEUS CAPITAL MANAGEMENT, L.P.
Shares:6.33M
Value:$10.75M
FAIRMOUNT FUNDS MANAGEMENT LLC
Shares:6.13M
Value:$10.41M
Summary
Showing Top 3 of 57